Comparison of Buprenorphine to Morphine in Treatment of Neonatal Abstinence Syndrome (NAS)
A Randomized Comparison of Sublingual Buprenorphine to Morphine Sulfate in the Treatment of Neonatal Abstinence Syndrome (NAS)
Sponsor: Pediatrix
This PHASE2 trial investigates Neonatal Abstinence Syndrome and Neonatal Withdrawal Syndrome and is currently completed. Pediatrix leads this study, which shows 10 recorded versions since 2012 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Feb 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Feb 2023 [monthly]
Completed PHASE2
-
Sep 2018 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 5 earlier versions
-
Jun 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE2
-
Apr 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
Status: Enrolling By Invitation → Active Not Recruiting
-
Feb 2018 — Apr 2018 [monthly]
Enrolling By Invitation PHASE2
-
Feb 2017 — Feb 2018 [monthly]
Enrolling By Invitation PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Enrolling By Invitation PHASE2
First recorded
Dec 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pediatrix
For direct contact, visit the study record on ClinicalTrials.gov .